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Cardiac biomarkers are associated with
maximum stage of acute kidney injury in
critically ill patients: a prospective analysis
Ryan Haines1, Siobhan Crichton2, Jessica Wilson1, David Treacher1 and Marlies Ostermann1*
Abstract
Background: This study aimed to investigate whether cardiac troponin T (cTnT), cardiac troponin I (cTnI) and
serum N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with acute kidney injury (AKI) and need
for acute renal replacement therapy (RRT) in adult patients admitted to the intensive care unit (ICU).
Methods: We analysed prospectively collected data for patients admitted to the ICU between June and December
2010 for non-cardiac reasons. The Kidney Disease Improving Global Outcomes creatinine criteria were applied to
identify patients with AKI including those who received acute RRT. Severity of illness was determined by the Acute
Physiology and Chronic Health Evaluation (APACHE) II score and the Serial Organ Failure Assessment (SOFA) score.
Regression analyses were performed to assess the association between cTnT, cTnI and NT-proBNP concentrations
on the first day of ICU stay, maximum AKI stages and need for acute RRT. Sensitivity analysis was performed in
which patients who developed a myocardial infarction during their stay in the ICU were excluded.
Results: Of 138 patients included, 73 (53%) had AKI and 40 (29%) required acute RRT. Patients with AKI were
significantly older, more likely to have sepsis and had higher APACHE II and SOFA scores on admission to the ICU.
In univariable analysis, cTnT, cTnI and NT-proBNP were significantly higher in those with AKI requiring acute RRT,
but after adjustment for baseline differences in severity of illness, cumulative fluid balance and pre-existing
comorbidities, only NT-proBNP remained significantly associated with worst stage of AKI and need for RRT. cTnT
and cTnI were independently associated with the odds of any AKI but not with need for RRT.
In a sensitivity analysis in which patients who had an acute myocardial infarction while in the ICU were excluded,
NT-proBNP remained independently associated with AKI and acute RRT.
Conclusions: In critically ill patients admitted to the ICU for non-cardiac reasons, admission NT-proBNP had the
strongest independent association with maximum stage of AKI and need for RRT.
Keywords: Acute kidney injury, Renal replacement therapy, Brain natriuretic peptide, Troponin, Biomarker
Background
Acute kidney injury (AKI) is a serious complication of
critical illness that affects more than 50% of patients ad-
mitted to the intensive care unit (ICU) [1, 2]. AKI is in-
dependently associated with short and long-term
complications, mortality and increased healthcare costs
[3]. There is an urgent need to identify patients who are
at risk of developing AKI in order to implement
renoprotective strategies and avoid nephrotoxic expo-
sures. Numerous novel biomarkers for AKI have been
tested in critically ill patients. Although several markers
have been found to indicate the onset of AKI before
serum creatinine increases, none has been integrated
into routine clinical practice [4].
A few studies have explored the role of cardiac bio-
markers in predicting AKI, the rationale being that car-
diac and renal function are closely linked (often referred
to as cardio-renal syndrome [5]). For instance, Thiengo
et al. [6] studied 29 ICU patients with incident sepsis
and concluded that cardiac troponin I (cTnI) on
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admission predicted the development of AKI and the
need for acute renal replacement therapy (RRT). Simi-
larly, a study in 34 consecutive ICU patients showed that
patients with AKI on presentation or during the ICU
stay had significantly higher levels of the cardiac bio-
marker brain natriuretic peptide (BNP) relative to pa-
tients without AKI [7].
These studies were relatively small, and larger studies
are required to confirm the findings. Our aim was to ex-
plore the relationship between the cardiac biomarkers
cTnI, cardiac troponin T (cTnT) and serum N-Terminal
pro-brain natriuretic peptide (NT-proBNP) and the
development of AKI and the need for RRT in a larger
patient cohort than previously undertaken.
Methods
We performed a sub-analysis of data that were collected
previously for a prospective observational study aimed at
exploring the epidemiology of troponin elevation in crit-
ically ill patients admitted to the ICU for non-cardiac
reasons [8].
Setting
Guy’s and St Thomas’ NHS Foundation Hospital is a
tertiary-care centre with a 43-bed level 3 multidisciplin-
ary adult ICU. The ICU has a fully computerized elec-
tronic patient record system in which all data are
recorded at the time of generation.
Patient population
As described previously [8], between June and December
2010 we enrolled consecutive adult patients (≥18 years)
who had been admitted to the ICU for non-cardiac rea-
sons. Patients with a high probability of cardiac injury or
a primary cardiac diagnosis at ICU admission were
excluded, specifically those with a clinical diagnosis of
myocardial infarction (MI) or out-of-hospital cardiac
arrest, patients who were post cardiac surgery or cardiac
intervention and patients admitted following thoracic
trauma with a high likelihood of myocardial injury. Pa-
tients were also excluded if they had been transferred
from another ICU, had previously been admitted to the
ICU during the same hospital stay or were expected to
remain in the ICU for <48 hours.
Patients were recruited within 36 hours of admission
to the ICU and blood was taken for measurement of
cTnT, cTnI and NT-proBNP. The blood samples were
stored at –70 °C until batch analysis at the end of the
study. For the purpose of this analysis, patients with pre-
existing end-stage renal failure (ESRF) were excluded.
Laboratory analysis
cTnT was measured using the Roche electrochemilumi-
nescent high-sensitivity sandwich immunoassay on the
Elecsys 2010. The quoted analytical range was 3–
10,000 ng/L, total coefficients of variation (CVs) were
1.5–3.4% (measured between 24 and 2665 ng/L) and the
reference range was <15 ng/L (99th percentile).
cTnI was measured using the Siemens Tnl-Ultra
three-site sandwich immunoassay on the Advia Centaur.
The quoted analytical range was 6–50,000 ng/L, total
CVs were 2.7–5.3% (measured between 80 and
27,200 ng/L) and the reference range was <39 ng/L.
NT-proBNP was measured using the Diagnostic
Products Corporation Immulite 2500 chemiluminescent
sandwich immunoassay. The analytical range was 20–
35,000 pg/ml, the quoted total CVs were 3.4–5.6% (mea-
sured between 40.9 and 32,096 pg/ml) and reference
range was <125 pg/ml in patients <75 years old and
<450 pg/ml in those >75 years old.
Data collection
We collected demographics, admission diagnosis, car-
diovascular risk factors (ischaemic heart disease (IHD),
diabetes, hypertension, any type of vascular disease),
Acute Physiology and Chronic Health Evaluation (APA-
CHE) II score, Sequential Organ Failure Assessment
(SOFA) score, serum creatinine, presence of sepsis and
ICU and hospital outcome. Cumulative fluid balance in
the first 24 hours in the ICU was determined from all
recorded fluid input and output data.
AKI was defined by the creatinine criteria of the
Kidney Disease Improving Global Outcomes (KDIGO)
classification [9, 10]. We recorded the maximum AKI
stage during ICU admission. The lowest serum cre-
atinine concentration within the previous 6 months
was used as baseline. If a baseline serum creatinine
was not available, we estimated it by back-calculation
using the Modification of Diet in Renal Disease
(MDRD) formula for an estimated glomerular filtra-
tion rate (eGFR) of 75 ml/min/1.73 m2 [10]. If the
patient was known to have pre-existing chronic kid-
ney disease (CKD) but a previous serum creatinine
result was not available, baseline serum creatinine
was again back-calculated for the relevant stage of
CKD using the MDRD formula as already described.
Treatment with RRT was recorded.
We also recorded whether patients had developed
an acute MI during ICU admission. The diagnosis of
MI was based on an elevated cTnT ≥ 15 ng/L and
contemporaneous ischaemic ECG changes according
to the most recent consensus criteria of the
European Society of Cardiology and American
College of Cardiology [11].
Statistics
Continuous data were summarized as the mean (stand-
ard deviation (SD)) or the median (interquartile range
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(IQR)) where the data were skewed, and were compared
between patients who did and did not develop AKI using
the t test or Mann–Whitney U test, as appropriate.
Categorical data were summarized as frequency (per-
centage) and compared using the chi-square test.
The AKI stage was defined as the maximum AKI stage
during admission. The associations between cardiac
troponin concentrations and odds of AKI were explored
using logistic regression models with development of
AKI defined in three different ways. The first set of
Table 1 Patient characteristics and outcomes
Parameter All (n = 138) No AKI (n = 65) Any AKI (n = 73) p value
Baseline characteristics
Age, median (IQR) 65.5 (49–76) 61 (41–72) 69 (54–77) 0.006
Male gender, n (%) 80 (58.0) 41 (63.1) 39 (53.4) 0.252
Comorbidities
IHD, n (%) 22 (15.9) 11 (16.9) 11 (15.1) 0.766
Hypertension, n (%) 49 (35.5) 21 (32.3) 28 (38.4) 0.459
Admission diagnosis category, n (%)
Acute kidney injury 8 (5.8) – 8 (11.0)
Cardiac emergency 6 (4.3) 3 (4.6) 3 (4.1)
Gastrointestinal emergency 13 (9.4) 8 (12.3) 5 (6.8)
Liver failure 3 (2.1) – 3 (4.1)
Metabolic emergency 4 (2.9) – 4 (5.5)
Neurological emergency/overdose 13 (9.4) 12 (18.5) 1 (1.4)
Post surgery 25 (18.1) 13 (20) 12 (16.4)
Respiratory failure 27 (19.6) 17 (26.1) 10 (13.7)
Sepsis 39 (28.3) 12 (18.5) 27 (37.0)
Parameters on admission to ICU
APACHE II, mean (SD) 19.4 (6.3) 16.2 (5.1) 22.2 (5.9) <0.001
SOFA score, mean (SD) 7.5 (3.7) 6.0 (3.0) 8.9 (3.8) <0.001
Lactate (μmol/L), median (IQR) 1.7 (1.1–3.3) 1.4 (0.9–2.1) 1.9 (1.2–4.5) 0.005
Bilirubin (μmol/L), median (IQR) 10 (7–19) 10 (6–14) 12 (7–30) 0.031
Sepsis, n (%) 39 (28.3) 12 (18.5) 27 (37.0) 0.016
Parameters in first 24 hours in ICU
Cumulative fluid balance (ml), median (IQR) 3196 (1606–5166) 2561 (1088–4023) 3730 (2316–5800) 0.002
No AKI, n (%) 77 (55.8) – 77 (55.8)
Any stage of AKI, n (%)
1 14 (10.1) – 14 (10.1)
2 14 (10.1) – 14 (10.1)
3 without RRT 5 (3.6) – 5 (3.6)
3 with RRT 28 (20.3) – 28 (20.3)
Outcomes
MI (in ICU), n (%) 20 (14.5) 9 (13.9) 11 (15.1) 0.839
Maximum stage of AKI stage during stay in ICU, n (%)
1 13 (9.4) – 13 (9.4)
2 12 (8.7) – 12 (8.7)
3 without RRT 8 (5.8) – 8 (5.8)
3 with RRT 40 (29.0) – 40 (29.0)
APACHE Acute Physiology and Chronic Health Evaluation, AKI acute kidney injury, ICU intensive care unit, IHD ischaemic heart disease, IQR interquartile range, MI
myocardial infarction, RRT renal replacement therapy, SD standard deviation, SOFA Sequential Organ Failure Assessment
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models were used to model odds of any AKI versus
none, the second set looked at stage 3 AKI versus lower
stage or no AKI and the third set modelled the odds of
need for RRT versus lower stage or no AKI. Troponin
concentrations were highly skewed and therefore were
log2 transformed prior to inclusion in the models to
meet the assumption of a linear relationship between
troponin level and the log odds. Results are therefore
expressed as an odds ratio (OR) which represents the
change in odds for a doubling of troponin level.
Multivariable logistic regression models were used to
adjust for baseline characteristics, with the number of
covariates included in the model reduced using principal
components analysis. Because of strong correlation be-
tween cTnI and cTnT, we analysed cTnI, cTnT and NT-
proBNP levels in separate models. A sensitivity analysis
was carried out in which patients who developed an MI
during their stay in the ICU before or after the develop-
ment of AKI were excluded. A second sensitivity analysis
was performed in which patients with any degree of AKI
on admission to ICU were excluded. The statistical ana-
lyses were carried out using Stata 14 MP.
Results
Of 144 patients recruited in the original study [8], six
were excluded due to pre-existing ESRF. As a result 138
patients were included in the analysis, of whom 73 (53%)
developed AKI. Thirteen patients (9.4%) had maximum
AKI stage 1, 12 patients (8.7%) had AKI stage 2 and 48
patients (35%) had AKI stage 3, of whom 40 were
treated with acute RRT. The median time between the
day of admission to the ICU and the day of the worst
AKI stage was 3 days.
Patients who developed AKI were significantly older,
had higher APACHE II and SOFA scores on admission
to the ICU, were more likely to have sepsis and had
higher serum bilirubin and lactate concentrations than
those without AKI (Table 1).
Univariable and multivariable analyses
In univariable analysis, cTnI, cTnT and NT-proBNP con-
centrations within the first 36 hours of ICU admission
were significantly higher in patients who developed AKI
or required RRT, with the odds of AKI increasing as
troponin increased (all p ≤ 0.001) (Table 2).
After adjustment for age, APACHE II score, gender,
hypertension, diabetes, IHD, sepsis, serum lactate, serum
bilirubin concentrations and cumulative fluid balance in
the first 24 hours in the ICU, NT-proBNP remained in-
dependently associated with odds of worst AKI stage
and need for RRT (Table 2). cTnT was independently as-
sociated with an increased odds of any AKI, as opposed
to none, and the development of maximum AKI stage 3
as opposed to a lower AKI stage, but there was no inde-
pendent association with need for RRT. cTnI was inde-
pendently associated with an increased odds of any AKI
Table 2 Associations between cardiac troponin I, cardiac troponin T and NT-proBNP and maximum stage of AKI
Cardiac biomarker Median (IQR), Median (IQR), Unadjusted
ORa (95% CI)
p value Adjustedb
ORa (95% CI)
Adjusteda
p value
Group 1 Group 2
Cardiac troponin I
Any AKI (1) vs no AKI (2) 0.14 (0.04–0.70) 0.03 (0.02–1.0) 1.37 (1.16–1.62) <0.001 1.20 (1.00–1.45) 0.044
Stage 3 AKI (1) vs lower stage (2) 0.22 (0.06 –1.03) 0.04 (0.02–0.16) 1.33 (1.14–1.54) <0.001 1.17 (0.98–1.41) 0.085
Stage 3 AKI with RRT (1) vs lower stage (2) 0.27 (0.06–1.03) 0.04 (0.02–0.19) 1.27 (1.10–1.40) 0.001 1.09 (0.90–1.32) 0.376
Cardiac troponin T
Any AKI (1) vs no AKI (2) 0.07 (0.04–0.16) 0.02 (0.01–0.05) 1.63 (1.32–2.01) <0.001 1.36 (1.06–1.74) 0.014
Stage 3 AKI (1) vs lower stage (2) 0.10 (0.05–0.21) 0.03 (0.01–0.07) 1.58 (1.28–1.96) <0.001 1.40 (1.06–1.84) 0.018
Stage 3 AKI with RRT (1) vs lower stage (2) 0.10 (0.05–0.21) 0.03 (0.01–0.08) 1.49 (1.21–1.83) <0.001 1.27 (0.95–1.69) 0.104
NT-proBNP
Any AKI (1) vs no AKI (2) 8888 (2504–18685) 1543 (239–5301) 1.41 (1.22–1.64) <0.001 1.23 (1.02–1.47) 0.027
Stage 3 AKI (1) vs lower stage (2) 10879 (2792–19797) 1609 (480–7055) 1.52 (1.27–1.82) <0.001 1.44 (1.14–1.82) 0.002
Stage 3 AKI with RRT (1) vs lower stage (2) 11302 (2792–21512) 1718 (531–7293) 1.48 (1.22–1.78) <0.001 1.40 (1.09–1.81) 0.008
NT-proBNP N-terminal pro-brain natriuretic peptide, AKI acute kidney injury, RRT renal replacement therapy, IQR interquartile range, CI confidence interval, OR odds
ratio, APACHE Acute Physiology and Chronic Health Evaluation
aORs estimated using logistic regression models with troponin levels log2 transformed. ORs represent the change in odds of AKI associated with a doubling of
troponin levels
bAdjusted for age, APACHE II score, gender, hypertension, diabetes, ischaemic heart disease, sepsis, lactate, bilirubin and cumulative fluid balance in the first
24 hours in the ICU (reduced to three principal components in models)
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but there was no association with development of AKI
stage 3 as opposed to a lower AKI stage.
Sensitivity analyses
Sensitivity analysis showed that NT-proBNP and cTnT
remained independent risk factors for AKI even when
patients who had a MI while in the ICU were excluded
(Table 3). NT-proBNP was also independently associated
with the need for RRT.
Additional file 1 presents the results of a sensitivity
analysis in which patients with any AKI on the day of
admission to the ICU were excluded. Patients with AKI
had significantly higher NT-proBNP concentrations.
Discussion
The key finding of this study was that analysis were that
in critically ill patients admitted for non-cardiac reasons,
NT-proBNP on admission to the ICU was independently
associated with the maximum stage of AKI, including
the need for RRT. The independent association persisted
after excluding patients who subsequently developed an
acute MI during their stay in the ICU. cTnT was inde-
pendently associated with AKI but not with need for
RRT. cTnI was not an independent risk factor.
NT-proBNP had the strongest association with worst
stage of AKI and need for RRT. NT-proBNP is a poly-
peptide secreted by the ventricles in response to exces-
sive stretching of cardiomyocytes and its role is to
promote natriuresis [12]. The link between ventricular
dilatation, raised central venous pressure (CVP) and
renal dysfunction is well established [13, 14] (Fig. 1). In
patients with a raised CVP, the increased backward pres-
sure propagates evenly in all districts of the venous sys-
tem, including renal veins. As a result, renal congestion
sets in and glomerular filtration and sodium excretion
decrease [15–19]. Physiologically, it makes sense that
NT-proBNP, a biomarker of ventricular dilatation, is as-
sociated with the development of AKI.
In patients with cardiac disease, BNP has been exten-
sively investigated and found to have added predictive
value for the development of AKI in patients with an
ST-elevation MI or heart failure [20, 21]. BNP has also
been described as a marker of the ‘cardio renal burden’
in patients admitted with a cardiac emergency and as a
risk factor for the development of AKI after cardiac
surgery [22–24].
To the best of our knowledge, the role of BNP as a
biomarker for AKI in critically ill patients presenting
without an acute cardiac emergency is limited to two
studies. de cal et al. [7] conducted a prospective trial in
34 ICU patients admitted with a non-cardiac diagnosis
and concluded that BNP levels predicted the develop-
ment of AKI. However, there was no adjustment for age
and severity of illness. Chou et al. [25] measured BNP
on admission to the ICU and 24 hours later in 163 crit-
ically ill patients, and showed that changes in BNP be-
tween the day of admission and 24 hours later predicted
the development of AKI, renal recovery and mortality.
Again, there was no adjustment for other important risk
factors, including severity of illness and underlying car-
diac risk factors.
The role of BNP in sepsis has also been studied [26, 27].
Papanikolaou et al. [26] measured BNP concentrations in
patients with sepsis and showed that BNP levels were
raised in sepsis and septic shock, presumably as a result of
pro-inflammatory cytokine release and biventricular dys-
function. However, the impact on renal function was not
assessed.
To our best knowledge this is the largest study which
demonstrates an independent association between NT-
proBNP concentration on admission to the ICU and
worst stage of AKI, including requirement for acute
RRT. Our conclusions are strengthened by the fact that
the association was maintained after exclusion of pa-
tients who developed an acute MI during their stay in
ICU and after adjustment for cumulative fluid balance. If
confirmed in future studies, NT-proBNP could serve as
an easily available ‘alert’ for AKI and RRT in routine
clinical practice.
However, it is important to acknowledge some po-
tential limitations. As a single-centre retrospective
study, the impact of unrecorded confounding factors
cannot be excluded. This is particularly important
when interpreting the association between NT-
proBNP and acute RRT because there is no consensus
about the optimal time of starting RRT and high vari-
ation in clinical practice. Second, we did not perform
routine echocardiography in all patients to correlate
the NT-proBNP results with ventricular dilatation and
acknowledge that other mechanisms beyond ventricu-
lar stretch may stimulate NT-proBNP release [28].
Third, pre-existing creatinine results were only avail-
able for 54 patients (39%). In the remaining 84 pa-
tients (61%), baseline renal function was estimated by
back-calculation using the MDRD formula. Although
this method is supported by the KDIGO working
group [9], we recognize that there are limitations, in-
cluding misclassification of AKI [17]. Fourth, we de-
fined sepsis according to the previous consensus
criteria because our study was conducted before the
new sepsis criteria were published [29]. Fifth, we cal-
culated cumulative fluid balance in the first 24 hours
in the ICU but did not include the fluid balance prior
to ICU admission. Finally, the exact aetiology of AKI
was not always documented by the treating clinical
team. Despite these limitations, we believe that our
findings are important and should prompt further re-
search to verify our results.
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Conclusions
In patients without a cardiac diagnosis on admission to
the ICU, admission NT-proBNP concentrations were in-
dependently associated with worst stage of AKI, includ-
ing need for acute RRT. The cTnT and cTnI results on
admission were associated with maximum stage of AKI
but not with need for RRT. Larger studies are needed to
evaluate the potential of NT-proBNP as a biomarker for
AKI and RRT.
Additional file
Additional file 1: Is a table presenting associations between cTnI, cTnT
and NT-proBNP and the odds of AKI – excluding patients with any degree
of AKI on day 1. (DOC 53 kb)
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